Progenics Pharmaceuticals (Progenics Pharmaceuticals) Debt-to-Equity : 1.73 (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Debt-to-Equity?

Progenics Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2020 was $7.86 Mil. Progenics Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2020 was $45.00 Mil. Progenics Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2020 was $30.61 Mil. Progenics Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2020 was 1.73.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Progenics Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

PGNX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Progenics Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Progenics Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Debt-to-Equity Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

Get a 7-Day Free Trial

0.47

0.78

0.44

1.17

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Debt-to-Equity	Get a 7-Day Free Trial															0.71	0.80	1.01	1.17	1.73

Competitive Comparison of Progenics Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Progenics Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Progenics Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Debt-to-Equity falls into.

Progenics Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Progenics Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.716	+	46.915)	/	46.553
	=	1.17

Progenics Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.856	+	44.998)	/	30.613
	=	1.73

Progenics Pharmaceuticals (NAS:PGNX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Progenics Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Executives

Asha Das	officer: Chief Medical Officer	C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli	director	SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman	10 percent owner, other: See Explanation of Responses	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria	10 percent owner, other: See Explanation of Responses	1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams	director
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022